Adjunctive Dapagliflozin Improves Glycemic Control in T1D
Dapagliflozin, when used as adjunct treatment to insulin, improves glycemic control in patients with type 1 diabetes.
Investigators examined safety and efficacy of adjunct therapy to insulin for patients with type 1 diabetes who are not adequately controlled.
It is critical for us to remember that children are not little adults. Pediatric-onset diabetes is different from adult-onset diabetes due to its distinct epidemiology, pathophysiology, developmental considerations, and response ...
The association between albumin-to-creatinine ratio and risk for diabetic nephropathy and CVD was examined over 2 to 4 years.